(Q43202922)

16 November 2017

A phase II study of doxifluridine and docetaxel combination chemotherapy for advanced or recurrent gastric cancer (English)

1 reference

16 November 2017

1 reference

Takaki Yoshikawa

1

1 reference

16 November 2017

Akira Tsuburaya

2

1 reference

16 November 2017

Ken Shimada

3

1 reference

16 November 2017

Atsushi Sato

4

1 reference

16 November 2017

Makoto Takahashi

5

1 reference

16 November 2017

Wasaburo Koizumi

6

1 reference

16 November 2017

Yasuo Yoshizawa

7

1 reference

16 November 2017

Kazuhito Nabeshima

8

1 reference

16 November 2017

Masayuki Kimura

9

1 reference

16 November 2017

Kiyoshi Hataya

10

1 reference

16 November 2017

Osamu Kobayashi

11

1 reference

16 November 2017

1 January 2009

1 reference

16 November 2017

1 reference

16 November 2017

12

1 reference

16 November 2017

212-218

1 reference

16 November 2017

4

1 reference

https://scigraph.springernature.com/pub.10.1007/s10120-009-0528-5

16 November 2017

0 references

cites work

Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10120-009-0528-5

Docetaxel plus cisplatin as second-line therapy in metastatic or recurrent advanced gastric cancer progressing on 5-fluorouracil-based regimen

21 January 2018

1 reference

12 December 2020

A phase II study of irinotecan and docetaxel combination chemotherapy for patients with previously treated metastatic or recurrent advanced gastric cancer

1 reference

12 December 2020

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group

1 reference

12 December 2020

Phase II study of docetaxel plus cisplatin as a second-line combined therapy in patients with advanced gastric carcinoma

1 reference

12 December 2020

[Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent gastric cancer: a Japanese Cooperative Study Group trial (group A)]

1 reference

12 December 2020

Phase II study of paclitaxel with 3-h infusion in patients with advanced gastric cancer

1 reference

12 December 2020

Combination chemotherapy with docetaxel and doxifluridine showed a beneficial outcome in advanced or recurrent breast cancer patients with longer disease-free interval.

1 reference

12 December 2020

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

1 reference

12 December 2020

Multi-center phase II study for combination therapy with paclitaxel/doxifluridine to treat advanced/recurrent gastric cancer showing resistance to S-1 (OGSG 0302).

1 reference

12 December 2020

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue

1 reference

12 December 2020

Docetaxel and oxaliplatin combination in second-line treatment of patients with advanced gastric cancer.

1 reference

12 December 2020

Epirubicin-docetaxel in advanced gastric cancer: two phase II studies as second and first line treatment

1 reference

12 December 2020

[Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group]

1 reference

12 December 2020

Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer

1 reference

12 December 2020

Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group

1 reference

12 December 2020

[Phase II study of 5'-deoxy-5-fluorouridine (5'-DFUR) in patients with malignant cancer--a multi-institutional cooperative study]

1 reference

12 December 2020

Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients

1 reference

12 December 2020

Role of uridine phosphorylase for antitumor activity of 5'-deoxy-5-fluorouridine.

1 reference

12 December 2020

Initial or delayed chemotherapy with best supportive care in advanced gastric cancer.

1 reference

12 December 2020

Reduced dose intensity of docetaxel plus capecitabine as second-line palliative chemotherapy in patients with metastatic gastric cancer: a phase II study

1 reference

12 December 2020

[A late phase II clinical study of RP56976 (docetaxel) in patients with advanced or recurrent gastric cancer: a cooperative study group trial (group B)]

1 reference

12 December 2020

Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts.

1 reference

12 December 2020

The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review

1 reference

12 December 2020

Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions

1 reference

12 December 2020

10.1007/S10120-009-0528-5

Identifiers

DOI

1 reference

16 November 2017

1 reference